Peptide Industry News

A patient-safety coalition wants the FDA to block compounding of seven peptides and to set aside the July advisory vote that endorsed six of...

Vanda's oral NK-1 blocker cut GLP-1 vomiting 27% in a Phase 3 trial, with an 81% drop in extreme cases. A supplemental FDA filing is planned...

A New Jersey federal judge refused to block Eli Lilly's weight-loss ads, finding Novo Nordisk failed to show irreparable harm. The false-adv...

Lilly has registered AMPLIFY-1 and AMPLIFY-2, two Phase 3 trials of its amylin-tirzepatide combination enrolling 3,115 patients, with comple...

Corxel Pharmaceuticals will merge with Amanat Acquisition Corp, raising about $377 million to fund Phase 3 testing of its once-daily oral GL...

Real-world records from nearly 48 million US adults show oral semaglutide initiation peaked 10 weeks after approval, briefly topping injecta...

A Texas federal judge denied Strive Specialties' bid to revive its antitrust suit against Eli Lilly and Novo Nordisk over compounded GLP-1 r...

Surging GLP-1 demand and telehealth prescribing have made provider follow-up the decisive safety factor in weight care, with dosing errors r...

Orforglipron met cardiovascular safety goals in ACHIEVE-4: MACE 4.2% vs 5.0% on insulin glargine, with A1C and weight benefits. What it mean...

Large randomized trials are testing whether GLP-1 medications like semaglutide can reduce alcohol and opioid cravings, expanding research fa...

GLP-1 users spend 26% more on fragrances, NIQ data shows, as dampened food reward shifts sensory pleasure toward scent and gourmand perfumes...

Novo Nordisk's post hoc REDEFINE 1 analysis reports 25% average weight loss in women on CagriSema at 68 weeks, consistent across menopause s...

Apothecary Pharma recalled 22 compounded tirzepatide vials nationwide after sterility could not be assured. FDA classed it Class II. What us...

The FDA is warning buyers about copycat GLP-1 drugs after a nationwide compounded tirzepatide recall. Here is how to check if your vial is l...

Which peptide treatments hold real FDA approval? PepsReview maps approved GLP-1 drugs against unapproved gray-market peptides and what it me...

A new consumer analysis of Wegovy vs. Ozempic highlights semaglutide brand confusion — and why that confusion feeds the gray market for unla...

One in six children on GLP-1s developed a nutritional deficiency within a year, claims study finds, with vitamin D shortfall leading at 12.4...

Twenty state attorneys general tell the State Department the FDA Green List lets Chinese suppliers ship unapproved GLP-1 ingredients into th...

Real-world OCTANE study: patients switching from GLP-1 injections to the semaglutide pill kept losing weight, 4.1% over three months....

Analysis of 636,525 records: escalating semaglutide to 2 mg tied to 6% lower cardiovascular risk than switching to tirzepatide....

NIH-funded UC Berkeley research shows semaglutide extended lifespan in older mice and improved muscle, memory, and blood sugar beyond calori...

FDA and HHS scrutiny of the peptide wellness market is tightening. PepsReview Editorial explains what regulatory analysis means for provider...

Peptide therapy runs $500 to $1,500 a month cash-pay while FDA decides if compounding BPC-157 and TB-500 stays legal — what patients risk in...

CHMP has recommended Eli Lilly's Foundayo (orforglipron) for EU approval — the first non-peptide GLP-1 pill, cleared for both obesity and ty...

Novo Nordisk South Africa has reported 39 suspected unlawful medicine cases in 2026, most tied to Instagram and WhatsApp sellers of illicit ...

South African drugmakers are urging police to prosecute illicit obesity-drug sellers, naming unapproved retatrutide sold openly by influence...

South Africa's pharmacy council and medicines regulator are rewriting compounding rules, with revised standards due for publication in March...

Lab testing in Ireland found significant impurities in 3 of 4 gray-market peptide products, with one Melanotan vial only 40% pure. HPRA seiz...

FDA inspection records reveal black mold, hidden paperwork, and fabricated documents at two Chinese plants supplying GLP-1 compounding ingre...

Hepatology specialists publish the first selection algorithm for resmetirom and semaglutide, the two FDA-approved MASH therapies for liver f...

FDA warning letters hit two online sellers of unapproved semaglutide branded as Indian-made products, with no valid U.S. approval and no pre...

Poison centers logged 862 bootleg retatrutide exposures from July to September 2026, nearly double the prior quarter, as FDA logs two death ...

Verdiva Bio terminated its Phase 2 weight-maintenance trial of oral GLP-1 VRB-101, citing a business decision. The monotherapy program conti...

Amylin weight-loss candidates from Novo Nordisk, Eli Lilly, and Zealand Pharma enter late-stage trials, with an FDA decision on CagriSema du...

Two deaths reported to the FDA have put bootleg Reta retatrutide under scrutiny. Here is what the reports do and do not show, and how to ver...

Oral semaglutide passed 100,000 US prescriptions in two months — the fastest weight-loss drug launch on record, an Annals of Internal Medici...

Eli Lilly files a second wave of lawsuits against five more companies selling unapproved retatrutide, pressing regulators to act as Phase 3 ...

Randomized-trial data show semaglutide slowed epigenetic aging clocks up to 9% in HIV lipodystrophy patients, with tirzepatide data emerging...

Months after the FDA called its Wegovy pill ad misleading, Novo Nordisk now markets to customers, not patients - and the gray market benefit...

The FDA flagged GLP-1 vision-loss signals in 2025, yet U.S. Ozempic and Mounjaro labels still carry no NAION warning while Europe and Austra...

FDA's proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list awaits a final decision. What it means for compo...

Lilly's FDA-approved Foundayo (orforglipron) is the first non-peptide GLP-1 weight-loss pill, with 12.4% trial weight loss and fast-growing ...

Novo Nordisk's first-in-class amycretin (zenagamtide) produced up to 14.6% weight loss and 1.71-point HbA1c cuts in a phase 2 diabetes trial...

Thousands of GLP-1 injury lawsuits advance while regulators admit data on serious harms stay thin. Here is what the evidence actually shows....

FDA warning letters target online peptide sellers, but overseas supply chains, mislabeled imports and $32M in quarterly crypto sales keep th...

Americans buying cheap online semaglutide may be paying the same Chinese chemical vendors that also sell fentanyl precursors, supply-chain a...

South Korea's drug regulator has approved Hanmi's EPPE, the first domestically developed GLP-1 obesity drug, based on Phase 3 data from 448 ...

The UK's Advertising Standards Authority has banned the first ads for oral GLP-1 weight loss medicines, targeting waitlist and pre-order mar...

Two new studies link GLP-1 medications to higher rates of hair loss, scalp inflammation and nail detachment — changes not explained by weigh...

Novo Nordisk will cut Wegovy's US list price by 50% to $675 a month from January 2027, with Ozempic down 35%, as competition reshapes the ob...

Full TRIUMPH-1 results confirm retatrutide produced 25% average weight loss at 80 weeks in peer-reviewed data. What the readout means for re...

Which GLP-1 drugs hold FDA approval for diabetes versus weight loss in 2026? PepsReview breaks down the labels, the off-label gap, and the r...

Hundreds of GLP-1 injury lawsuits now sit in New Jersey courts. PepsReview breaks down the claims, the timeline and what it means for resear...

Lilly's ACHIEVE-4 trial shows oral GLP-1 Foundayo met cardiovascular safety goals while cutting weight and A1C in adults with type 2 diabete...

South Africa's largest private health plan reports GLP-1 claims nearly tripled to 61,200 members — while members claim for just 5.4 months o...

GLP-1 prescribing for US children ages 8-11 rose 310-fold from 2019 to 2026, a Pediatrics study finds — mostly off-label and concentrated in...

FDA approved 22 novel drugs in Q3 2026, including peptide therapeutics enlicitide and rusfertide. What the quarter means for rare disease pa...

The FDA's warning on unapproved GLP-1 drugs gains urgency as retatrutide poison-center exposures surge 265% — here is what researchers must ...

The FDA closes 2026 with seven pivotal decisions, led by bepirovirsen's October 26 hepatitis B ruling plus calls on obinutuzumab and bezucla...

Lilly's EloraTZP — eloralintide plus tirzepatide — delivered up to 23.3% weight loss and deep A1C cuts at 48 weeks, with Phase 3 starting be...

Federal prosecutors unsealed charges against two Dubai men for smuggling counterfeit Ozempic from China — a scheme that allegedly outlasted ...

Northwestern scientists showed an experimental RNA therapy reprogrammed fat to burn calories, preserving lean mass during semaglutide weight...

A regulator-mandated Scandinavian registry study of 97,464 semaglutide users found no increased pancreatic cancer risk, reinforcing GLP-1 sa...

Real-world data on 636,525 adults links semaglutide dose escalation to 6% lower MACE risk vs switching to tirzepatide. What researchers shou...

GLP-1s are now sold as lifestyle products for 'customers' rather than medicines for patients — reshaping supply, oversight, and peptide mark...

The unregulated peptide market is projected to reach $50-75 billion by 2028 as FDA rulemaking stalls and clinicians warn of impurities and a...

The TAME metformin longevity trial has FDA-agreed design but zero participants after a decade — a case study in off-patent drug research fun...

A records study of 300M+ U.S. health charts finds 1.1M adults got GLP-1 prescriptions with no approved medical reason and higher eating-diso...

An attorney describes life-changing GLP-1 drug injuries in the growing lawsuit against Novo Nordisk and Eli Lilly — what researchers need to...

Actimed completes PROACT Phase 2a enrollment, testing whether S-pindolol benzoate preserves muscle during and after semaglutide therapy in o...

FDA sent August 2026 warning letters to four DTC peptide sellers over unapproved-drug marketing, even as the 503A compounding pathway loosen...

A national claims analysis found 16.8% of pediatric GLP-1 users developed nutritional deficiencies within a year, led by vitamin D; counseli...

The FDA's latest GLP-1 compounder warning letter cites contamination risk from insanitary production conditions. What it means for peptide q...

A new lawsuit alleges manufacturers and PBMs colluded on insulin and GLP-1 pricing. What the case means for drug costs and gray-market pepti...

Eli Lilly's once-weekly basal insulin cleared the FDA, escalating its rivalry with Novo Nordisk. What the decision means for clinics and res...

A new Cureus FAERS analysis examines musculoskeletal adverse event signals for semaglutide, liraglutide, and tirzepatide, the latest increti...

Viking's VK2735 maintenance trial kept up to 97% of weight loss after stepping down to monthly or biweekly GLP-1/GIP dosing, with placebo-li...

Roche's enicepatide cut HbA1c by 2.65% and drove 15.5% weight loss in a Phase 2 diabetes trial, setting up Phase 3 programs starting in 2027...

The FDA's September 2026 warning letter takes aim at Empower Pharmacy's GLP-1 production - the latest in a multi-year pattern of quality fai...

Twenty state attorneys general seek tighter FDA Green List oversight of GLP-1 ingredient imports after a listed Chinese supplier relabeled s...

The FDA has hit a Sinopep subsidiary with an import ban suspending its peptide API sales to the US — what researchers need to know about it....

Biophytis files an amendment to extend OBA, its Phase 2 trial pairing the muscle-preserving candidate BIO101 with semaglutide in adults with...

New clinical-practice data suggest oral GLP-1 tablets curb snacking less than injections, with modest but real dietary shifts in adults with...

Novo courts restive investors with consumer-health plans and blockbuster pipeline bets as Eli Lilly tightens its grip on the obesity market....

FDA escalates warnings on compounded GLP-1 drugs while its own adverse-event data reveal gaps — and what both sides mean for peptide researc...

Novo Nordisk's CagriSema posted 12.4% weight loss versus 9.1% for tirzepatide in phase 3, with an FDA weight-management decision expected in...

A 63,000-patient records study links higher semaglutide doses to fewer new psychiatric diagnoses, independent of how much weight patients lo...

GLP-1 development accelerates in 2026 even as NAION vision-loss lawsuits grow. What the pipeline expansion means for researchers....

NAION vision-loss claims against GLP-1 makers have reached 216 consolidated federal cases in MDL-3166, with Mounjaro users among the newest ...

Ozempic's higher-dose era: a 2 mg weekly injection plus FDA-cleared oral tablets in 1.5, 4 and 9 mg strengths — and what the wider brand mea...

FDA warning letters and legal analysis confirm 'Research Use Only' labels don't protect peptide vendors. What it means for buyers and resear...

Novo Nordisk sued Eli Lilly in federal court over allegedly misleading Zepbound and Mounjaro ad campaigns, seeking a permanent injunction an...

A 1.4 million-patient study links GLP-1 drugs to lower ascites rates and reduced all-cause mortality in MASH, with one small liver-cancer si...

Eli Lilly filed six lawsuits against retatrutide sellers marketing the unapproved obesity drug to consumers, part of a widening enforcement ...

Health Canada approved Sandoz Semaglutide, the first generic version of Ozempic — a milestone for GLP-1 access and affordability in Canada....

A new study finds GLP-1 drugs produce weight loss at low starter doses with significantly less nausea, but results unlikely to match higher-...

Newly filed lawsuits blame Mounjaro and Ozempic for sudden vision loss, extending GLP-1 eye-damage litigation to both Eli Lilly and Novo Nor...

An FDA advisory panel recommended six peptides for pharmacy compounding in July 2026. The agency has yet to rule, and clinicians urge cautio...

Alabama's attorney general leads a state coalition framing exploitation of FDA-approved drugs by China's supply chain as a US national secur...

Novo Nordisk and Eli Lilly have filed for South Korean approval of their oral GLP-1 obesity pills, setting up a launch race in one of Asia's...

Novo Nordisk exits its $285 million once-monthly GLP-1 pact with Ascendis Pharma, returning rights as its pipeline reset deepens ahead of a ...

Federal Open Payments data shows Eli Lilly and Novo Nordisk paid over 270,000 US doctors to promote GLP-1 weight-loss drugs, one receiving u...

A new study links GLP-1 weight-loss drugs to a rare brain disorder driven by thiamine depletion from rapid weight loss — what researchers ne...

No GLP-1 patch has FDA approval. Every licensed GLP-1 is an injection or tablet, and peptide chemistry blocks skin delivery. What researcher...

Wegovy users with sudden vision loss are being recruited for NAION claims as semaglutide litigation expands - what regulators found and how ...

Thailand moved weight-loss injection pens to prescription-only from September 15, 2026, ending over-the-counter GLP-1 sales and targeting un...

A counterfeit product sold as a peptide contained a large semaglutide dose and hospitalized a New Zealand user, exposing unregulated injecta...

Novo Nordisk rebrands as Novo with a new logo and a cultural reset as it battles Eli Lilly for the GLP-1 obesity market. What it means for r...

Dr. Michael Burgess urges FDA to end its GLP-1 Green List after a relabeled Chinese semaglutide case and 21% noncompliance among foreign API...

GLP-1 vision-loss litigation expands beyond tirzepatide as Saxenda users are recruited for NAION claims over liraglutide. What researchers s...

Australian authorities renew warnings after a patient suffered a torn oesophagus following use of an unapproved peptide bought outside regul...

GLP-1 litigation over Eli Lilly's Zepbound is active in federal court in 2026. Who may qualify to file, the injuries alleged, and what court...

Updated September 2026 claims in the Empower Pharmacy lawsuit target compounded GLP-1s, FDA warning letters, and testing gaps. What buyers s...

FDA has run a coordinated enforcement sweep against peptide sellers marketing unapproved products, amid a wider Washington debate over acces...

A free evidence checker for peptide claims has launched as verification tools multiply across the research peptide market. What buyers shoul...

A new market intelligence index catalogs 100+ peptide vendors, 3,200+ listings and 112,000+ public COA records. How researchers can use it r...

Oral GLP-1 prescriptions keep climbing as the Wegovy pill and Lilly's oral tablet ramp up. What the tablet shift means for researchers and b...

Aggressive marketing, compounded copies, and purity concerns have put the GLP-1 weight-loss market under fire. Here is what researchers need...

FDA approves Eli Lilly's oral GLP-1 weight-loss pill, a needle-free option that reshapes obesity care, telehealth supply, and compounded GLP...

Semaglutide supply has recovered, ending the shortage that fueled compounded copies. The enforcement window is closing on gray-market GLP-1 ...

Retatrutide still has no FDA approval in 2026. What the Phase 3 TRIUMPH timeline means for researchers and why gray-market vials carry real ...

Third-party analytical testing for research peptides is scaling up as purity and mislabeling complaints grow. What stronger verification mea...

New data show GLP-1 prescriptions rising in children under 12 as semaglutide trial results reshape pediatric obesity care and safety scrutin...

China has approved semaglutide (Wegovy) as the first GLP-1 treatment for MASH liver disease, opening a new regulatory and research frontier....

Lawsuits linking Zepbound and Trulicity to NAION vision loss are mounting against Eli Lilly, raising fresh safety questions for the GLP-1 cl...

Moonwalk has raised $70M to move a fat-targeting RNAi obesity candidate into clinical development, adding a new mechanism to the obesity pip...

Novo Nordisk's IL-6 inhibitor failed two more cardiovascular outcome trials, a setback for inflammation-driven heart disease research beyond...

UK regulators froze over £200,000 in bank accounts and seized thousands of illicit GLP-1 doses in Operation Dunlin — what researchers need t...

Compounded semaglutide and tirzepatide have drawn more than 1,700 federal adverse event reports. We break down the FDA data and what it mean...

South Africa's High Court refused a compounding pharmacy's appeal in the semaglutide fight with Novo Nordisk, keeping the sales ban in force...

Medicine-safety monitors highlight researchers' blunt warning that clinical evidence for most consumer peptides is missing — how to grade pe...

Clinicians are raising safety concerns as peptide self-medication goes mainstream. Verification standards protect researchers as enforcement...

FDA is screening GLP-1 ingredients (semaglutide, tirzepatide) at U.S. borders and warns of vials labeled with pharmacies that do not exist. ...

Discover how peptide purity testing cost varies based on method, scope, and location. Learn to compare options for relia...

GLP-1 Cost Comparison: How to Get the Best Price Per Milligram. Price per mg across vendors (forum data: <$1/mg is good,...